
According to the Guide, the registrant of the medical device is responsible for implementing a suitable QMS for the product realization process.

The NMPA announced new administrative measures designed to increase the post-market surveillance applicable to all registered medical devices sold in China.

The principles describe the manufacturing requirements to ensure the medical device operates safely and performs as intended。

AUSSENWIRTSCHAFT AUSTRIA and Cisema cohost the webinar to talk about the regulatory changes for both medical device and cosmetic industries.

Medical devices approved by the NMPA or the Ministry of Food and Drug Safety of Korea can apply for the MDACS listing in Hong Kong within a trial period

The prevention and control work were deployed as the top priority, and the registration process of some overseas medical products was expedited.

NMPA provides a regulatory pathway for CMDs to meet the special clinical demands for medical institutions in China to treat designated patients.

Cisema will submit a proposal to the NMPA about the draft regulation before the consultation period ends on 31.03.2020. If you are interested to contribute, please provide your input to us

On 4.3.2020, the China-Britain Business Council (CBBC) and Cisema held a webinar together to talk about the market, regulations and standards for overseas medical device products to enter the China market. Our business consultant, Anna King, provided an overview of the approval systems for NMPA registration in China and the recent implementation of urgent measures to expedite the approval procedures for medical and health products due to the CoronaVirus outbreak.Watch the recording of the webinar on Youtube.

New product certification regulation from organization CCAP for automobile lighting, external plastic parts and break disks

The Israel Export Institute co-hosted a webinar together with Cisema to introduce the China administration bodies, regulations and standards for cosmetics.

Currently, there are 14 municipalities with the capacity to file non-special purpose cosmetics, and Cisema can guide you through the MPA filing process.

On 04.02.2020, the authorities SAMR (State Administration for Market Regulation) and CNCA (China National Certification Administration) published in their Notice No 9/2020 general support measures to contain the corona virus outbreak. Chinese certification organizations are bound by these requirements.The measures include:

The Ministry of Commerce announced the list of intermediary services and administrative examinations and approvals for import and export of goods in China.

Cisema has the capability to help you comply with Hong Kong MDACS requirements and expand your businesses in the Greater Bay Area

On 27.12.2019, the China Ministry of Finance, General Administration for Market Regulation and 11 other ministries announced (No.96-2019) the List of Cross-border E-commerce Retail Imported Commodities (2019 edition) covering a total of 1413 types of commodities. The list added roughly 100 types of goods, and removed 8 types from the 2018 edition. According to China Customs, products on the list are exempted from submitting related import licenses. When entering the special trade zone, the commodites on the list will be checked by customs in accordance with the standard procedures for clearing commodities, but will then be exempted when leaving the special trade zone. The updated list came into effect on 01.01.2020.On 24.12.2019, the Chinese State Council announced (No.36-2019) that the State Taxation Administration had approved the establishment of 24 pilot cross-border e-commerce (CBEC) zones - in addition to the 35 pilot CBEC zones that have previously been established - and introduced exemptions on value-added tax and consumption tax for retail and exported goods. The approved document announces the initial plan of how the trial zones will be constructed and replicated across China. More detailed information regarding tax rebates, government support, and international logistic services are expected to follow after this announcement.Please do contact us to know if your products are involved.

On 06.11.2019, the China NDRC (National Development and Reform Commission) announced (No.20-2019) the prohibition of daily chemical articles containing plastic microbeads for production after December 31, 2020, and for sale after December 31, 2022.Microbeads are small plastic particles, mostly included in cosmetic and cleaning products, and are known to cause water pollution to the marine and freshwater environments. Currently, 14 states have already taken action towards the ban on microbeads. Although the details of the ban for production and sales in China is still subject to further refinement, brands and manufacturers are expected to reformulate their products containing microbeads, while some have already replaced microbeads with natural abrasives as an alternative in daily chemical articles.The announcement (No.20-2019) is based on the Industrial Structure Adjustment Guidance Catalogue (2019 Edition) that was approved at the 2nd committee meeting on 27.08.2019, and has replaced the 2011 version since 01.01.2020.

On 20.12.2019, the China NMPA (National Medical Products Administration) announced (No.91-2019) that it would add 148 medical devices and 23 in-vitro diagnostic reagents to the clinical trial exemption list, as well as to revise the names and descriptions of 48 medical devices and 4 in-vitro diagnostic reagents. Medical devices and in-vitro diagnostic reagents on the clinical trial exemption list won’t require completion of clinical trials in order to achieve NMPA certification.This new clinical trial exemption list is effective since the date of announcement on 20th December.Feel free to contact us if you would like to know what products were included in the clinical trial exemption list for medical devices, and the clinical trial exemption list for IVDs.

The China NMPA (National Medical Products Administration) is seeking input on whether real world data can be used for Clinical Evaluation Reports. This is a potentially very significant development and Cisema will submit a proposal to the NMPA before the consultation period ends on 13 January 2020.

On November 12, 2019, the SAMR published the Health Food Naming Guideline 2019 for the naming rule of China registered and filed health food.
And discover how we can support you.